NCT04244019
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have been treated with stereotactic radiosurgery (SRS)
Exclusions: Patients that do NOT have a new intracranial lesion with clinical & radiographic findings suspicious for either radionecrosis or tumour progression; Patients who have had previous radiotherapy to the intended treatment area
https://ClinicalTrials.gov/show/NCT04244019